Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Swipe for next article

Independent Bulletin homepage

Download our
Social Partner

We are 8 logo (opens in a new tab)

Drug maker Indivior to delist its shares from London Stock Exchange

Drugs firm Indivior has said it is considering moving its shares to the US public markets (Kirsty O’Connor/PA) — Drugs firm Indivior has said it is considering moving its shares to the US public markets (Kirsty O’Connor/PA) (PA Archive)

Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange (LSE) on July 25, following its primary listing move to the US's Nasdaq index last year.
The company cites reduced costs and complexity, along with the fact that over 80% of its revenue is generated in the US, as reasons for the delisting.
Indivior also noted that liquidity on the Nasdaq now significantly surpasses that of the LSE, with a greater level of trading activity.
Indivior's chairman, David Wheadon, stated that a single primary listing on Nasdaq best reflects the profile of Indivior’s business.
Despite Indivior's exit, the LSE welcomes Valterra Platinum, Anglo American’s platinum spin-off, after becoming independent from the mining giant.

Drug maker Indivior to abandon London stock market for the US — In full